Quantcast

Latest Prostate Stories

2014-10-21 08:34:00

NEW YORK, Oct. 21, 2014 /PRNewswire/ -- Honoring one's Hispanic heritage is about more than just celebrating your roots, it is about bringing awareness of issues that affect your community. Prostate cancer is the most common cancer among Hispanic man, affecting 1-in-7 during their lifetime. Dr. David Samadi, chief of urology at Lennox Hill Hospital in New York City, is urging Latin women to have the men in their lives get a simple blood test as a way to screen their prostate health....

2014-10-17 00:21:14

SAN DIEGO, Oct. 16, 2014 /PRNewswire/ -- GenomeDx Biosciences today announced that a draft local coverage determination (LCD) for its Decipher® Prostate Cancer Classifier has been published by the Centers for Medicare and Medicaid Services (CMS) describing a coverage and payment policy for use of the Decipher test in men who have undergone radical prostatectomy. An LCD is a decision by Medicare contractors to cover an item or service. Decipher is the only genomic test for prostate...

2014-10-14 12:29:42

WASHINGTON, Oct. 14, 2014 /PRNewswire-USNewswire/ -- ZERO - The End of Prostate Cancer recently awarded the Jim Lafferty Memorial Research Grant in the amount of $45,000 to Peter Carroll, M.D., M.P.H., of UC San Francisco for the purpose of researching new and improved methods for early detection of prostate cancer. The grant is part of the ZERO Cancer Research Fund, charged with supporting innovative, high-reward research that offers the best return on investment for patients and...

2014-10-09 08:27:36

ProMark(TM) Validated to Predict Disease Aggressiveness and Empower Informed Treatment Decisions CAMBRIDGE, Mass., Oct. 9, 2014 /PRNewswire/ -- Metamark announced today the nationwide availability of ProMark(TM), the first-of-its-kind protein-based biopsy test designed to improve the accuracy of prognosis for men diagnosed with prostate cancer. For the 205,000 men annually with indeterminate Gleason scores (3+3 and 3+4), ProMark can help identify aggressiveness of the disease....

2014-10-02 08:29:14

Study will assess ability of VolitionRx NuQ® to distinguish between aggressive anaplastic prostate cancer and typical castration-resistant prostate cancer (CRPC) NAMUR, Belgium, Oct. 2, 2014 /PRNewswire/ --VolitionRx Limited (OTCQB: VNRX), a life sciences company focused on developing blood-based diagnostic tests for different types of cancer, today announced a study collaboration with The University of Texas MD Anderson Cancer Center's Department of Genitourinary Medical Oncology. The study...

2014-09-30 08:32:22

Trelstar® one-, three-, and six-month dosing options now available TORONTO and LAUSANNE, Switzerland, September 30, 2014 /PRNewswire/ -- Trelstar(R) (triptorelin pamoate), indicated in Canada for the palliative treatment of hormone dependent advanced prostate cancer,[1] is now available in a six-month dosing option (22.5 mg). The new dosing option eases the burden on patients, with a decreased number of injections and a low incidence of injection site pain, while providing...

2014-09-30 08:30:47

Prostate Cancer Canada grant aims to accelerate pace of discovery of novel therapies TORONTO, Sept. 30, 2014 /CNW/ - Prostate Cancer Canada is in a race to give the approximately 24,000 Canadian men diagnosed with prostate cancer each year a better fighting chance. In response to the urgent need to increase the pace of discovery, Prostate Cancer Canada just awarded a Translation Acceleration Grant (TAG) to a team led by Dr. Paul Rennie of the Vancouver Prostate Centre and the...

2014-09-29 16:25:57

Additional Tests to Demonstrate the Importance of Utilizing Multiple Biological Pathways to Provide Patients, Physicians with Confidence to Make Educated Treatment Decisions CAMBRIDGE, Mass., Sept. 29, 2014 /PRNewswire/ -- Metamark announced today the expansion of its prostate cancer test services to now include the PROGENSA(®) PCA3 assay, a urine-based test that can help confirm negative prostate biopsies, and ERG, a companion test to the company's existing PTEN assay. These tests...

2014-09-29 16:24:13

TORONTO, Sept. 29, 2014 /CNW/ - The following B-Roll is available by Video On-Demand web download: STORY SUMMARY -- Prostate Cancer Canada is in a race to give the approximately 24,000 Canadian men diagnosed with prostate cancer each year a better fighting chance. In response to the urgent need to increase the pace of discovery, Prostate Cancer Canada will be funding breakthrough research into a new generation of drugs that used alone or in combination with other therapies will...

2014-09-29 08:31:04

Strongly Positive Results, Presented at European Society for Medical Oncology (ESMO) 2014 Congress, Demonstrated Oncotype DX® Prostate Cancer Test was an Independent Predictor of Tumor Aggressiveness REDWOOD CITY, Calif., Sept. 29, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced strongly positive results from an additional independent clinical validation study of the Oncotype DX® prostate cancer test, conducted in collaboration with the Uniformed Services University...


Latest Prostate Reference Libraries

Prostate
2013-03-04 15:21:55

The male prostate gland acts as an exocrine gland in the male reproductive system. It is a firm, partly muscular, chestnut sized gland near the neck of the urethra in males. Formation and Orientation The prostate is usually formed within the ninth week of the embryonic stage in reproductive development. The prostate can be separated into either “lobes” or “zones”. When looking at a prostate divided into zones, there are four distinct regions. The first zone is the Peripheral...

More Articles (1 articles) »
Word of the Day
negawatt
  • A unit of saved energy.
Coined by Amory Lovins, chairman of the Rocky Mountain Institute as a contraction of negative watt on the model of similar compounds like megawatt.